OC
ADIL

Oppenheimer & Co’s Adial Pharmaceuticals ADIL Stock Holding History

Oppenheimer & Co’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-62
Closed -$13K – 1349
2022
Q3 		$13K Hold
62
– – ﹤0.01% 1350
2022
Q2 		$52K Hold
62
– – ﹤0.01% 1362
2022
Q1 		$77K Hold
62
– – ﹤0.01% 1421
2021
Q4 		$104K Hold
62
– – ﹤0.01% 1444
2021
Q3 		$165K Buy
62
+17
+38% +$35.6K ﹤0.01% 1417
2021
Q2 		$71K Buy
45
+22
+96% +$33.5K ﹤0.01% 1479
2021
Q1 		$35K Buy
+23
New +$34.8K ﹤0.01% 1424

Other funds holding ADIL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Oppenheimer & Co's ADIL Position: Q4 2022 in Review

Oppenheimer & Co sold out of Adial Pharmaceuticals (ADIL) in Q4 2022, closing a stake of 62 shares — an estimated $13K sold.

Oppenheimer & Co first reported a position in ADIL in Q1 2021 and held it in 7 quarters. The position peaked at $165K in Q3 2021. 20 funds tracked by Wall St. Rank hold ADIL as of Q4 2022.

  • Oppenheimer & Co reported no remaining Adial Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 62 Adial Pharmaceuticals shares in Q4 2022, an estimated $13K.
  • Oppenheimer & Co first reported a position in Adial Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Oppenheimer & Co's Adial Pharmaceuticals position peaked at $165K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q4 2022.

Based on Oppenheimer & Co's 13F filing for Q4 2022, filed 8 Feb 2023.